INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- On September 11, 2020, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who ...

Dulaglutide (Trulicity) effectively boosted blood glucose control in youth with type 2 diabetes, the AWARD-PEDS trial found. Over the 26-week trial, 51% of youth (ages 10 to <18 years) treated with ...

SAN FRANCISCO -- The GLP-1 receptor agonist dulaglutide (Trulicity) slowed renal function decline in some patients with type 2 diabetes and poor kidney functioning, researchers said here, and they ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

"Continuing to research our medicines beyond the initial clinical trial program is important for patients and for the ongoing study of diabetes," said Brad Woodward, M.D., senior medical director, ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...

The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of ...

diabetes test strip Findings from a phase 3 study showed that dulaglutide (Trulicity; Lilly) at higher investigational doses demonstrated superiority in significantly reducing hemoglobin A1c in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA approved two additional doses of ...